Chiron Capital Management’s TG Therapeutics TGTX Stock Holding History

Chiron Capital Management’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$209K	Buy	+3,800	New	+$156K	0.19%	127
2023 Q3	–	Sell	-9,500	Closed	-$236K	–	127
2023 Q2	$236K	Sell	9,500 -2,600	-21%	-$67.2K	0.19%	91
2023 Q1	$182K	Buy	12,100 +1,483	+14%	+$22.5K	0.13%	113
2022 Q4	$126K	Buy	+10,617	New	+$77.1K	0.09%	117
2022 Q3	–	Sell	-10,717	Closed	-$46K	–	130
2022 Q2	$46K	Sell	10,717 -2,975	-22%	-$18.6K	0.03%	125
2022 Q1	$130K	Buy	13,692 +1,920	+16%	+$22.2K	0.08%	118
2021 Q4	$224K	Buy	+11,772	New	+$306K	0.16%	102
2020 Q4	–	Sell	-4,425	Closed	-$118K	–	404
2020 Q3	$118K	Buy	+4,425	New	+$102K	0.1%	96

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return

Chiron Capital Management's TGTX Position: Q2 2026 in Review

Chiron Capital Management opened a new position in TG Therapeutics (TGTX) in Q2 2026: 3,800 shares worth $209K. The stake represents 0.19% of the portfolio and ranks #127 among its holdings. This is a return to the name: Chiron Capital Management previously reported a position in TGTX as recently as Q2 2023.

Chiron Capital Management first reported a position in TGTX in Q3 2020 and has held it in 8 quarters since. The position peaked at $236K in Q2 2023. 431 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Chiron Capital Management held 3,800 shares of TG Therapeutics worth $209K as of Q2 2026.
TG Therapeutics was a new Chiron Capital Management position in Q2 2026.
TG Therapeutics made up 0.19% of Chiron Capital Management's portfolio in Q2 2026, its #127 holding.
Chiron Capital Management first reported a position in TG Therapeutics in Q3 2020 and has held it in 8 quarters since.
Chiron Capital Management's TG Therapeutics position peaked at $236K in Q2 2023.
431 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Chiron Capital Management's 13F filing for Q2 2026, filed 21 Jul 2026.